about
Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cellsGenetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancerPhase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis.The role of the E-cadherin/catenin complex in gastrointestinal cancer.Echium oil is not protective against weight loss in head and neck cancer patients undergoing curative radio(chemo)therapy: a randomised-controlled trialG-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy.Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.Optimisation of pharmacy content in clinical cancer research protocols: Experience of the United Kingdom Chemotherapy and Pharmacy Advisory Service.The distress thermometer predicts subjective, but not objective, cognitive complaints six months after treatment initiation in cancer patients receiving a curative cancer treatment.Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment.Functional and molecular characterization of the epithelioid to round transition in human colorectal cancer LoVo cells.hMSH6 deficiency and inactivation of the alphaE-catenin invasion-suppressor gene in HCT-8 colon cancer cells.Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.Use of the Freund clock drawing test within the Mini-Cog as a screening tool for cognitive impairment in elderly patients with or without cancer.The use of uHear™ to screen for hearing loss in older patients with cancer as part of a comprehensive geriatric assessment.Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.Implementation of uHear™--an iOS-based application to screen for hearing loss--in older patients with cancer undergoing a comprehensive geriatric assessment.Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenPARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study.Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium.ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.Integration of geriatric oncology in daily multidisciplinary cancer care: the time is nowA call for rigorous research and transparent study reporting …Themes for our journal: 2014-2016Organization, quality and cost of oncological home-hospitalization: A systematic reviewAdherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in BelgiumShifting specialized oncological care from hospital- to home-setting: is there support among patients, specialists and general practitioners?Health related quality of life in older patients with solid tumors and prognostic factors for declineScreening Methods for Age-Related Hearing Loss in Older Patients with Cancer: A Review of the LiteratureDetermining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgeryFibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With SunitinibThe added value of an assessment of the patient's hand grip strength to the comprehensive geriatric assessment in G8-abnormal older patients with cancer in routine practiceQuality of blood samples collected at home does not affect clinical decision making for the administration of systemic cancer treatmentPSMA expression on neovasculature of solid tumorsSubjective, but not objective, cognitive complaints impact long-term quality of life in cancer patientsThe prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (≥ 70 years) patients with different cancer tumors
P50
Q28235080-70C63C2B-78EB-4E23-B317-208523B538DDQ33422082-30D643FA-76E5-4FE3-9A9C-0A6C1F9C986BQ33423436-917D72C1-3B91-44E7-B408-199368FCF735Q33610075-94F4358B-2C98-4DCE-AAD6-7DDDBD4AB550Q33848988-354CBE02-E4C2-4910-851F-297A405DB3D7Q34354878-D9060E15-B66A-4A65-A8EE-60D6DE5E517DQ35836618-3F9BEA93-C065-4CC7-A152-831419C28686Q36385639-8AF4CAF6-2159-4AAC-BCBF-190FA54829A1Q38161531-F2BB3BE9-9E50-4079-A180-66E7E715E73AQ38344488-129EA0D6-BAE1-40C1-B446-4D5AB12CE270Q38620477-26105B56-87CC-4754-BA72-ADA35244DC3CQ39659802-5BE7D779-FBFE-402C-B321-B4E470EBC0DBQ40625650-E5621986-67C1-4273-909F-300ED5551163Q40864619-B72D9101-DFCB-4F5B-8883-18D4CEB9877AQ41735562-D7B62889-A8CD-47CD-B969-98D2AF425FA8Q44743043-44511C86-B72D-46B0-A3C9-0BD7498C517BQ47642505-A6F9388B-8A88-4752-8D4E-BFAC6F0D626AQ47672449-CBC2F2BE-733D-4D56-AB05-231D376B7336Q49069110-941A3055-DEE8-420E-8CD5-0158A704835FQ50135460-27214A08-3863-4842-9544-20EA0C24DF17Q50142327-8F43ABA6-8164-48D8-92A8-14ADEAF01E43Q50493114-06AE352D-850A-40B0-B2C3-1EC55863B82EQ53062408-92406F9F-C2A9-4B9C-9EA1-6902C5566FE8Q54335451-F26F1A44-8BD8-4E33-BF84-8437F4A45B6EQ54978437-D408CC21-F84E-45B1-B4AB-412C85DDD2A6Q86822082-5B2CC623-4D3E-4009-9880-E1F570C09EFAQ86961145-AD40253C-0636-4540-841A-7412FA0431C7Q87736298-22EA3CAD-7E92-4584-A784-AF3A02D723E5Q88668303-F3D230A7-CF12-4316-8204-E123D2B1640AQ89113354-61806DA9-10BF-48D0-8186-78EB3A25C8A3Q90021499-F627B3D2-F09D-4DC7-928D-D917C97A932EQ90040971-D2EB5D1F-48D2-4772-80AB-E3DF5CF7E209Q90214648-0B5644A0-5BA6-4A48-A32D-9F411EF157B8Q90235940-F0D03F62-9650-4DAB-9B85-2B1AD0E07004Q90348408-FD08DD82-57ED-4781-B747-EA62E809832BQ91029448-1FBF5721-4CE8-4363-BE10-67FBFE24CD42Q91857767-3A04FB1C-C3FA-42F9-8257-83260E64BA58Q91862240-F36B8FFB-EBCA-4073-A404-5E123FC0D5BBQ91863407-CE510D1F-F647-438B-A585-214BC0D22968Q92036405-E6E0B5BA-FD49-4922-972D-EBE2DBE48B6F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Philip R Debruyne
@nl
Philip R Debruyne
@sl
Philip R. Debruyne
@en
Philip R. Debruyne
@es
type
label
Philip R Debruyne
@nl
Philip R Debruyne
@sl
Philip R. Debruyne
@en
Philip R. Debruyne
@es
prefLabel
Philip R Debruyne
@nl
Philip R Debruyne
@sl
Philip R. Debruyne
@en
Philip R. Debruyne
@es
P106
P1153
6602806881
P21
P31
P496
0000-0001-5438-9697